What this means for obesity and heart disease patients
While there are current therapies available for people living with obesity and heart disease, the introduction of a one-step drug for both can make living with both conditions much more manageable, both physically and mentally.
On the physical side, taking Wegovy can help those living with obesity reach and maintain a healthy weight. Losing weight can reduce the risk of MACE, but the drug’s added benefit can perpetuate that benefit even further.
On the mental side, weight loss in those living with obesity, as well as a reduced risk of heart attack, can improve a person’s level of anxiety and stress related to their conditions.
“People deserve evidence-based care to proactively manage this disease, including medical nutrition therapy, psychological interventions, physical activity, pharmacotherapy and surgery,” said Dr. Sanjeev Sockalingam, Scientific Director of Obesity Canada, in the release.
Overall, Wegovy, with its proven effects on both weight management and MACE, paints a picture of a future where people can reach and maintain a healthy weight while also improving their heart’s ability to function long term.